Status:
COMPLETED
Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants
Lead Sponsor:
HilleVax
Conditions:
Gastroenteritis
Eligibility:
All Genders
5-5 years
Phase:
PHASE1
Brief Summary
This is a phase 1, randomized, double-blind multi-center, placebo-controlled trial in Japan to evaluate the safety and immunogenicity of HIL-214 in healthy infants 5 months of age (-14/+14 days) at fi...
Detailed Description
The rationale for trial NOR-109 is to evaluate the safety and immunogenicity of HIL-214 in Japanese pediatric subjects and establish whether the data obtained is consistent with that previously obtain...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Male or female subject aged 5 months \[-14/+14 days\].
- Infants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
- The subject's legally acceptable representative (LAR) signs and dates a written, informed consent form (ICF) and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.
- The subject's LAR is willing and able to comply with trial procedures and is available for the duration of follow-up.
- Exclusion Criteria
- Clinically significant abnormality in growth by length/height, weight, or head circumference (according to national guidelines).
- Gastrointestinal abnormalities or any chronic gastrointestinal disease, including any uncorrected congenital malformation of the gastrointestinal tract according to medical history and/or physical examination.
- Chronic use of oral corticosteroids (equivalent to 20 mg/day prednisolone for ≥12 weeks / ≥2 mg/kg body weight /day for ≥2 weeks) within 60 days prior to Visit 1 (use of inhaled, intranasal, or topical corticosteroids are allowed).
- Use of parenteral corticosteroids (equivalent to 20 mg/day prednisolone for ≥12 weeks / ≥2 mg/kg body weight /day for ≥2 weeks. Use of inhaled, intranasal, or topical corticosteroid is allowed) within 60 days prior to Visit 1.
- Receipt of immunostimulants within 60 days prior to Visit 1.
- Receipt of parenteral, epidural, or intra-articular immunoglobulin (Ig) preparations, blood products, and/or plasma derivatives within 90 days prior to Visit 1 or planned during the full duration of the trial.
- Receipt of immunosuppressive therapy prior to Visit 1.
- Known hypersensitivity or allergy to any of the trial vaccine components (including excipients).
- Any clinically significant active infection (as assessed by the investigator) or temperature ≥38.0°C (\>100.4°F), regardless of method used, within 3 days prior to intended trial vaccine administration.
- Gastroenteritis within 7 days before planned dosing (can warrant delay of trial vaccine administration).
- History of, e.g., convulsions/febrile convulsions, or any illness, that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the subjects due to participation the trial.
- Abnormalities of splenic or thymic function.
- Known or suspected impairment/alteration of immune function.
- Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- Receipt or scheduled receipt of any other approved or authorized vaccines within 14 days (for all non-live vaccines or oral live vaccines) or 28 days (for parenteral live vaccines) before or after trial vaccine administration.
- Participation in any clinical trial with another investigational product 30 days prior to first trial visit or intention to participate in another clinical trial at any time during the conduct of this trial.
- Seropositive for, or in evaluation for, possible human immunodeficiency virus infection.
Exclusion
Key Trial Info
Start Date :
August 18 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 27 2024
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT06007781
Start Date
August 18 2023
End Date
May 27 2024
Last Update
March 14 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Fukui Aiiku Hospital
Fukui-shi, Japan, 910-0833
2
Iizuka Children's Clinic
Iizuka-Shi, Japan, 820-0040
3
Childrens Clinic of Kose
Kofu, Japan, 400-0853
4
Ohigesenseino Kodomo Clinic
Sapporo, Japan, 062-0907